Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On March 23, 2023, we reported on a study published in JAMA Cardiology that evaluated the prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease (ASCVD) by race and ethnicity.
Researchers pooled participant data for 3 NHANES cycles between 2013 and 2020, representing nearly 40 million US adults. The team calculated 10-year predicted ASCVD risk for participants using the pooled cohort equation (PCE) and divided risk into quartiles, from 5% to <7.5% up ≥20%.
The final cohort numbered 3417 participants with a median age of 61.8 years; race and ethnicity were by self-report and weighted percentages were: Asian, 4.2%, Black, 12.7%, Hispanic, 10.1%, and White 73.0%.
Among participants with a guideline indication for statin therapy, treatment was substantially lower for Black and Hispanic participants compared with White participants in the overall cohort (20.0% vs 27.9%, P<.001, and 15.4% vs 27.9%, P<.001, respectively) as well as across ASCVD strata.
Statin use in the highest risk strata (≥20%) was low overall and was significantly lower among Black participants (23.8; prevalence ratio [PR], 0.90; 95% [CI, 0.82 - 0.98) and Hispanic participants (23.9%; PR, 0.90; 95% CI, 0.81 - 0.99) compared with White participants (37.6%; reference group).
Note from authors
The findings “demonstrate the persistent racial and ethnic disparities in guideline-recommended statin use among at-risk adults and represent an opportunity to advance pharmacoequity in primary prevention.”